Development of strategic approaches to therapy of infections caused by multiresistant Acinetobacter baumannii

For many years, standard therapy for infections caused by A.baumannii has been administration of beta-lactam antibiotics often in combination with aminoglycosides in cases of severe infections. However, most of hospital-acquired А. baumannii are currently resistant to these agents. Fluoroquinolones, tetracyclines and glycilcyclines, trimetoprim-sulfamethoxazole, carbapenems (excluding ertapenem) and polymyxins can preserve activity in respect of some hospital-acquired infections. However, rapid increase in resistance to these groups of antibiotics is observed in most countries. Therefore, it is necessary to develop strategic approaches to therapy of infections caused by multiresistant Acinetobacter baumannii. Monotherapy with ampicillin/sulbactam at a dose of 24 g/day or combination therapy regimens including carbapenems and ampicillin/sulbactam or carbapenems and cephoperason/sulbactam and netilmicin are justified.